A randomized, multicenter, phase III study of gemcitabine combined with capecitabine versus gemcitabine alone as first-line chemotherapy for advanced pancreatic …
Background: This phase III trial compared the efficacy and safety of gemcitabine plus
capecitabine (GemCap) versus single-agent gemcitabine (Gem) in advanced pancreatic
cancer as first-line chemotherapy. Methods: A total of 214 advanced pancreatic cancer
patients were enrolled from 16 hospitals in South Korea between 2007 and 2011. Patients
were randomly assigned to receive GemCap (oral capecitabine 1660 mg/m 2 plus Gem
1000 mg/m 2 by 30-minute intravenous infusion weekly for 3 weeks followed by a 1-week …
capecitabine (GemCap) versus single-agent gemcitabine (Gem) in advanced pancreatic
cancer as first-line chemotherapy. Methods: A total of 214 advanced pancreatic cancer
patients were enrolled from 16 hospitals in South Korea between 2007 and 2011. Patients
were randomly assigned to receive GemCap (oral capecitabine 1660 mg/m 2 plus Gem
1000 mg/m 2 by 30-minute intravenous infusion weekly for 3 weeks followed by a 1-week …